NEAL PATEL: Open Payments
NPI 1861020091 · LARGO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,691 in 149 payments from 20 companies in 2025. Trend: 2023 $1,201 · 2024 $808 · 2025 $2,691
Food & beverage: $2,691
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $368 |
| ABBVIE INC. | 14 | $318 |
| Teva Pharmaceuticals USA, Inc. | 32 | $314 |
| Neurocrine BioSciences, Inc. | 13 | $300 |
| Supernus Pharmaceuticals, Inc. | 14 | $212 |
| Axsome Therapeutics, Inc. | 6 | $172 |
| Alkermes, Inc. | 8 | $160 |
| Noven Therapeutics, LLC | 8 | $157 |
| Janssen Pharmaceuticals, Inc | 6 | $132 |
| E.R. Squibb & Sons, L.L.C. | 5 | $125 |
Products named: CAPLYTA, VRAYLAR, INGREZZA, AUSTEDO XR, Qelbree, Auvelity, ARISTADA, Xelstrym.
Industry payments across FL — which companies pay providers there.
